PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Reinmuth, N; Bryl, M; Bondarenko, I; Syrigos, K; Vladimirov, V; Zereu, M; Bair, AH; Hilton, F; Liau, K; Kasahara, K

Reinmuth, N (reprint author), Asklepios Lung Clin Munich Gauting, Dept Thorac Oncol, Robert Koch Allee 2, D-82131 Gauting, Germany.

BIODRUGS, 2019; 33 (5): 555

Abstract

Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Ava......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索